X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
NBL-001 (volasertib) is a PLK-1 inhibitor, small molecule drug candidate. It is being evaluated for the treatment of relapsed/refractory acute myelogenous leukemia.
Lead Product(s): Volasertib
Therapeutic Area: Oncology Product Name: NBL-001
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Boehringer Ingelheim GmbH
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 22, 2024
Details:
CPX-POM (fosciclopirox) is a patented, parentally administered prodrug of a commercially available topical antifungal agent, ciclopirox. It is under phase 1/2 clinical development for the treatment of bladder cancer and Acute Myeloid Leukemia (AML).
Lead Product(s): Fosciclopirox
Therapeutic Area: Oncology Product Name: CPX-POM
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: CicloMed LLC
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 18, 2023
Details:
The Merger will focus on developing new precision medicines through Notable’s proprietary Predictive Precision Medicines Platform. NBL-001 (volasertib) is derived from PPMP and is a highly potent PLK1 inhibitor inducing cell cycle arrest and apoptosis in cancer cells.
Lead Product(s): Volasertib
Therapeutic Area: Oncology Product Name: NBL-001
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: VBL Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger October 16, 2023
Details:
The Merger will create a company developing new precision medicines through Notable’s proprietary Predictive Precision Medicines Platform (PPMP). NBL-001 (volasertib) is derived from PPMP and is a highly potent PLK1 inhibitor inducing cell cycle arrest and apoptosis in cancer cells.
Lead Product(s): Volasertib
Therapeutic Area: Oncology Product Name: NBL-001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Notable stockholders Builders VC
Deal Size: $10.3 million Upfront Cash: Undisclosed
Deal Type: Private Placement October 16, 2023
Details:
The Merger will create a clinical-stage therapeutic platform company developing new precision medicines through Notable’s proprietary PPMP. NBL-001 (volasertib) is derived from PPMP and is a highly potent PLK1 inhibitor inducing cell cycle arrest and apoptosis in cancer cells.
Lead Product(s): Volasertib
Therapeutic Area: Oncology Product Name: NBL-001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: VBL Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger February 23, 2023
Details:
Notable’s lead asset derived from PPMP is NBL-001 (volasertib), a highly potent PLK1 inhibitor proven to induce cell cycle arrest and apoptosis in various cancer cells.
Lead Product(s): Volasertib
Therapeutic Area: Oncology Product Name: NBL-001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Builders VC
Deal Size: $10.3 million Upfront Cash: Undisclosed
Deal Type: Private Placement February 23, 2023
Details:
Under the terms of co-development agreement, CicloMed holds the responsibility for executing clinical trial operations while Notable is focused on optimizing Notable’s predictive precision medicine platform with the goal of assessing patient responsiveness to fosciclopirox.
Lead Product(s): Fosciclopirox,Cytarabine
Therapeutic Area: Oncology Product Name: CPX-POM
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: CicloMed LLC
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement December 01, 2021
Details:
Under the terms of this agreement, Oncoheroes will retain the license for the development and commercialization of volasertib for pediatric cancers and continue its commitment towards childhood cancer.
Lead Product(s): Volasertib
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Oncoheroes Biosciences Inc.
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement November 11, 2021
Details:
Volasertib is a Polo-like kinase 1 (PLK-1) inhibitor with demonstrated activity in AML and other tumor types with significant unmet medical need. Company plan to fast-track volasertib’s development with phase 2/3 clinical trials in AML and other cancers.
Lead Product(s): Volasertib,Cytarabine
Therapeutic Area: Oncology Product Name: NBL-001
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 11, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
